49 results on '"Ng, Kok Pin"'
Search Results
2. Frontotemporal dementia and COVID‐19: Hypothesis generation and roadmap for future research
3. Author Correction: [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease
4. [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease
5. Anosognosia predicts default mode network hypometabolism and clinical progression to dementia
6. Predicting functional decline in aging and Alzheimer’s disease with PET-based Braak staging
7. Modelling the Distribution of Cognitive Outcomes for Early-Stage Neurocognitive Disorders: A Model Comparison Approach
8. Visual Cognitive Assessment Test: Utility of the brief cognitive battery for early screening of cognitive impairment in Chongqing, China
9. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease
10. Normative data for baseline and longitudinal neuropsychological assessments in Singapore
11. Dementia in Southeast Asia: influence of onset-type, education, and cerebrovascular disease
12. Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals
13. Characterizing biomarker features of cognitively normal individuals with ventriculomegaly
14. The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework
15. The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database
16. Corrigendum: Topology of diffusion changes in corpus callosum in Alzheimer's disease: An exploratory case-control study
17. C9orf72 expansions are the most common cause of genetic frontotemporal dementia in a Southeast Asian cohort
18. Corrigendum: Topology of diffusion changes in corpus callosum in Alzheimer's disease: An exploratory case-control study (Frontiers in Neurology, (2022), 13, (1005406), 10.3389/fneur.2022.1005406)
19. Topology of diffusion changes in corpus callosum in Alzheimer's disease: An exploratory case-control study
20. Additional file 1 of APOE4 carrier status determines association between white matter disease and grey matter atrophy in early-stage dementia
21. APOE4 carrier status determines association between white matter disease and grey matter atrophy in early-stage dementia.
22. Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease
23. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease
24. In vivo quantification of neurofibrillary tangles with [18F]MK-6240
25. Alzheimer's Disease Blood Biomarkers Associated With Neuroinflammation as Therapeutic Targets for Early Personalized Intervention
26. IVIG treatment in non-paraneoplastic Lambert- Eaton myasthenic syndrome with elevated voltage- gated calcium channels antibodies and subacute cerebellar ataxia
27. Topology of diffusion changes in corpus callosum in Alzheimer's disease: An exploratory case-control study
28. Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer's disease continuum
29. Role of Cognitive Enhancer Therapy in Alzheimer’s Disease with Concomitant Cerebral White Matter Disease: Findings from a Long-Term Naturalistic Study
30. Amyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression
31. Additional file 1 of Dementia in Southeast Asia: influence of onset-type, education, and cerebrovascular disease
32. The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study
33. [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer's disease.
34. Association between white matter hyperintensity load and grey matter atrophy in mild cognitive impairment is not unidirectional
35. The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study
36. Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia
37. Cerebrovascular Disease Is a Risk for Getting Lost Behavior in Prodromal Dementia
38. Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy
39. Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease.
40. The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia
41. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain
42. Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?
43. In vivo quantification of neurofibrillary tangles with [18F]MK-6240.
44. Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer's disease continuum.
45. Frontotemporal dementia and COVID-19: Hypothesis generation and roadmap for future research.
46. Agitation and impulsivity in mid and late life as possible risk markers for incident dementia.
47. Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [ 18 F]THK5351 uptake in progressive supranuclear palsy.
48. Characterizing biomarker features of cognitively normal individuals with ventriculomegaly.
49. Monoamine oxidase B inhibitor, selegiline, reduces 18 F-THK5351 uptake in the human brain.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.